We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
Cap. Flow
+$1.16B
Cap. Flow %
36.62%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$16.4M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$9.99M
3
TSLA icon
Tesla
TSLA
+$7.93M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.52%
2 Healthcare 9.63%
3 Energy 0.42%
4 Industrials 0.14%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
276
Xencor
XNCR
$1.76B
– –
-171,275
Closed -$1.59M
VIRX
277
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-19
Closed -$2.91M
VIRX
278
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-4
Closed -$650K
SEEL
279
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$26K
SEEL
280
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$130K
ALIM
281
CALL
DELISTED
Alimera Sciences
ALIM
– –
-46
Closed -$376K
ALIM
282
DELISTED
Alimera Sciences
ALIM
– –
-3,333
Closed -$271K
ALIM
283
PUT
DELISTED
Alimera Sciences
ALIM
– –
-33
Closed -$266K
NBSE
284
CALL
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-2
Closed -$62K
EIGR
285
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-158
Closed -$743K
ICPT
286
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-55
Closed -$1.3M
INFI
287
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-5,438
Closed -$79.2K
ACGN
288
DELISTED
Aceragen Inc
ACGN
– –
-773
Closed -$2.48M
AMPE
289
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-469
Closed -$497K
AMPE
290
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-5
Closed -$497K
HSTO
291
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-240
Closed -$347K
ARNA
292
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-27,478
Closed -$1.12M
ARNA
293
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-415
Closed -$1.74M
GWPH
294
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-250
Closed -$2.02M
GNMX
295
PUT
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-145
Closed -$75K
ECYT
296
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-159
Closed -$97K
ECYT
297
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-11,300
Closed -$69K
ECYT
298
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-863
Closed -$525K
CORI
299
DELISTED
Corium International, Inc.
CORI
– –
-130,732
Closed -$803K
ANTH
300
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-85
Closed -$131K
9 10 11
12
13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.